Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Business
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
    • ICAS Talk
    • Warwick Business School
    • The University of Bath
    • AON
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • Schroders Talk
    • eToro Talk
    • IG Talk
    • M&A Talk
    • BCB Talk
  • Crypto A.M.
    • Crypto News
    • CoinCorner Talk
  • Opinion
    • Features
    • Letters
    • The City View
  • Jobs and Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Doceo
    • The Business Guide
    • Finance & Legal
  • Unwind
    • Unwind
    • Sport
    • Six Nations 2022
    • The Punter
    • The Punter Podcast
    • Culture
    • Life & Style
    • Sport Business
    • The Magazine
    • Travel
    • Discover Malta
    • Green Economy
    • The DiverCity Podcast
    • Aramco Team Series
    • Queen’s Award 2022
    • Health, Fitness, and Wellbeing
  • Charity
    • Giving
    • World’s biggest donors 2010 – 2021
  • Latest Paper
  • Jobs

GlaxoSmithKline

  • Landmark year: GSK beats quarterly expectations as it plans consumer healthcare spin off

    GSK RESULTS

    Healthcare giant GlaxoSmithKline has reiterated its growth outlook after posting first quarter sales of £9.8bn, surpassing analysts’ expectations. The pharmaceutical firm said it anticipated it would deliver sales growth in 2022 of between five to seven per cent at CER and growth of adjusted operating profit of between 12 to 14 per cent at CER. [...]

  • GlaxoSmithKline clinches cancer specialist Sierra Oncology in $1.9bn deal

    $1.9BN DEAL

    Healthcare giant GSK has snapped up Sierra Oncology, a late-stage biopharmaceutical company focused on rare forms of cancer treatments.

  • GlaxoSmithKline will not begin any new clinical trials in Russia

    GSK announcement

    Britain’s second-biggest drug maker, GlaxoSmithKline, won’t begin any new clinical trials in Russia because of the war against Ukraine. It made the announcement following similar moves by major US pharmaceutical giants Pfizer, Merck and Eli Lilly. The UK’s biggest company in the industry, AstraZeneca, is still conducting trials – but is considering ending them, according [...]

  • GSK looks for covid jab approval as it prepares to spin off consumer arm

    February 23, 2022

    GlaxoSmithKline and French drugmaker Sanofi have announced they are seeking regulatory approvals for their joint covid vaccine as the firms scramble to catch up with competitors after a series of delays.

  • GlaxoSmithKline revels in £8.8bn profit ahead of consumer healthcare demerger

    February 9, 2022

    GlaxoSmithKline (GSK) has reported full-year sales of £34bn, boosted by strong pharmaceutical sales over the past 12 months.

  • GSK science chief to depart as pharma giant looks to revamp drugs pipeline

    January 19, 2022

    GlaxoSmithKline's chief scientific officer Hal Barron will leave the firm this year to join a Silicon Valley anti-ageing start up.

  • Bankers prepare £25bn package as private equity firms circle GSK

    January 17, 2022

    Bankers are putting together major financing packages in preparation of a potential private equity bid for GlaxoSmithKline’s consumer healthcare business.

  • ‘Marmite situation’ for GSK investors as Unilever bids spark potential bidding war 

    January 17, 2022

    Analysts have predicted a potential bidding war erupting for GSK’s consumer arm.

  • Unilever share price dives 7 per cent as £50bn battle for GlaxoSmithKline’s consumer business begins in earnest

    January 17, 2022

    The main City story this morning is the £50bn bid by Unilever for GlaxoSmithKline’s consumer healthcare business, of which it owns a 68 per cent stake along with Pfizer, which Glaxo said it had rejected. “No doubt in the hope that Unilever will come back with a higher offer, with the sum of £60bn being [...]

  • Healthcare regulator approves GlaxoSmithKline drug for severely ill Covid patients in UK

    December 2, 2021

    A drug treatment which, the makers say, works against the new Omicron variant of Covid-19, has been approved by UK regulators. Xevudy (sotrovimab), made by pharmaceutical giant GlaxoSmithKline (GSK), has been found to cut hospital admission and death by 79% in those at risk. The monoclonal antibody has been authorised by the Medicines and Healthcare [...]

Posts navigation

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 13
  • Next

Trending Articles

  • EY working to spin off its audit business in biggest shakeup of any Big Four firm in two decades

  • Jaguar Land Rover's owner threatens move to Slovakia following row with UK ministers

  • Exclusive: KPMG to hire 3,500 tech workers to staff newly launched digital products business

  • Brexit: UK ports introduce customs clearance fees in 'bulls**t money-making exercise' to recoup lost revenues

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2019

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2022 City A.M. Limited